ArticleCritical care explorations2025
Personalized Fluid Management in Patients With Sepsis and Acute Kidney Injury: A Causal Machine Learning Approach.
Article in Critical care explorations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence to Facilitate SEP-1 Measure Compliance and Fluid Management in Sepsis.Journal of clinical medicine · 2026Review
Corrections and comments
- Update of
Authors and funding
21 authors.
Funding
Abstract
importanceIV fluids are the cornerstone for management of acute kidney injury (AKI) after sepsis but can cause fluid overload. A restrictive fluid strategy may benefit some patients; however, identifying them is challenging. Novel causal machine learning (ML) techniques can estimate heterogenous treatment effects (HTEs) of IV fluids among these patients.
objectivesTo develop and validate a causal-ML framework to identify patients who benefit from restrictive fluids (< 500 mL fluids within 24 hr after AKI). DESIGN SETTING AND
participantsWe conducted a retrospective study among patients with sepsis who developed acute kidney injury (AKI) within 48 hours of ICU admission. We developed a causal-ML approach to estimate individualized treatment effects and guide fluid therapy. We developed the model in Medical Information Mart for Intensive Care IV and externally validated it in Salzburg Intensive Care database. MAIN OUTCOMES AND MEASURES: Our primary outcome was early AKI reversal at 24 hours. Secondary outcomes included sustained AKI reversal and major adverse kidney events by 30 days (MAKE30). Model performance to identify HTE of restrictive IV fluids was assessed using the area under the targeting operator characteristic curve (AUTOC), which quantifies how well a model captures HTE, and compared with a random forest model.
resultsCausal forest model outperformed random forest in identifying HTE of restrictive IV fluids with AUTOC 0.15 vs. -0.02 in external validation cohort. Among 1931 patients in external validation cohort, the model recommended restrictive fluids for 68.9%. Among these, patients who received restrictive fluids demonstrated significantly higher rates of early AKI reversal (53.9% vs. 33.2%, CONCLUSIONS AND RELEVANCE: Causal-ML framework outperformed random forest model in identifying patients with AKI and sepsis who benefit from restrictive fluid therapy. This provides a data-driven approach for personalized fluid management and merits prospective evaluation in clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.